TY - JOUR
T1 - The ERA-EDTA registry annual report 2017
T2 - A summary
AU - Kramer, Anneke
AU - Boenink, Rianne
AU - Noordzij, Marlies
AU - Bosdriesz, Jizzo R.
AU - Stel, Vianda S.
AU - Beltrán, Palma
AU - Ruiz, Juan C.
AU - Seyahi, Nurhan
AU - Farnés, Jordi Comas
AU - Stendahl, Maria
AU - Garneata, Liliana
AU - Winzeler, Rebecca
AU - Golan, Eliezer
AU - Lopot, František
AU - Korejwo, Grzegorz
AU - Bonthuis, Marjolein
AU - Lassalle, Mathilde
AU - Slon Roblero, Maria F.
AU - Kuzema, Viktorija
AU - Hommel, Kristine
AU - Stojceva-Taneva, Olivera
AU - Asberg, Anders
AU - Kramar, Reinhard
AU - Hemmelder, Marc H.
AU - de Meester, Johan
AU - Vazelov, Evgueniy
AU - Andrusev, Anton
AU - de la Nuez, Pablo Castro
AU - Helve, Jaakko
AU - Komissarov, Kirill
AU - Casula, Anna
AU - Magaz, Ángela
AU - de Pablos, Carmen Santiuste
AU - Bubic, Ivan
AU - Traynor, Jamie P.
AU - Ioannou, Kyriakos
AU - Idrizi, Alma
AU - Palsson, Runolfur
AU - des Grottes, Jean Marin
AU - Spustova, Viera
AU - Tolaj-Avdiu, Miloreta
AU - Jarraya, Faical
AU - Nordio, Maurizio
AU - Ziginskiene, Edita
AU - Massy, Ziad A.
AU - Jager, Kitty J.
N1 - Funding Information: The ERA-EDTA Registry is funded by the ERA-EDTA. This article was written by Kramer et al. on behalf of the ERA-EDTA Registry, which is an official body of the ERA-EDTA. In addition, M.F.S.R. reports personal fees from NxStage outside the submitted work and K.J.J. reports grants from the ERA-EDTA during the conduct of the study and a speaker fee from Fresenius Medical Care outside the submitted work. Publisher Copyright: © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background. This article presents a summary of the 2017 Annual Report of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry and describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 37 countries. Methods. The ERA-EDTA Registry received individual patient data on patients undergoing RRT for ESRD in 2017 from 32 national or regional renal registries and aggregated data from 21 registries. The incidence and prevalence of RRT, kidney transplantation activity and survival probabilities of these patients were calculated. Results. In 2017, the ERA-EDTA Registry covered a general population of 694 million people. The incidence of RRT for ESRD was 127 per million population (pmp), ranging from 37 pmp in Ukraine to 252 pmp in Greece. A total of 62% of patients were men, 52% were ≥65 years of age and 23% had diabetes mellitus as the primary renal disease. The treatment modality at the onset of RRT was haemodialysis for 85% of patients. On 31 December 2017, the prevalence of RRT was 854 pmp, ranging from 210 pmp in Ukraine to 1965 pmp in Portugal. The transplant rate in 2017 was 33 pmp, ranging from 3 pmp in Ukraine to 103 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2008-12, the unadjusted 5-year patient survival probability for all RRT modalities combined was 50.8%.
AB - Background. This article presents a summary of the 2017 Annual Report of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry and describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 37 countries. Methods. The ERA-EDTA Registry received individual patient data on patients undergoing RRT for ESRD in 2017 from 32 national or regional renal registries and aggregated data from 21 registries. The incidence and prevalence of RRT, kidney transplantation activity and survival probabilities of these patients were calculated. Results. In 2017, the ERA-EDTA Registry covered a general population of 694 million people. The incidence of RRT for ESRD was 127 per million population (pmp), ranging from 37 pmp in Ukraine to 252 pmp in Greece. A total of 62% of patients were men, 52% were ≥65 years of age and 23% had diabetes mellitus as the primary renal disease. The treatment modality at the onset of RRT was haemodialysis for 85% of patients. On 31 December 2017, the prevalence of RRT was 854 pmp, ranging from 210 pmp in Ukraine to 1965 pmp in Portugal. The transplant rate in 2017 was 33 pmp, ranging from 3 pmp in Ukraine to 103 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2008-12, the unadjusted 5-year patient survival probability for all RRT modalities combined was 50.8%.
KW - Dialysis
KW - End-stage renal disease
KW - Epidemiology
KW - Kidney transplantation
KW - Survival analysis
UR - http://www.scopus.com/inward/record.url?scp=85090639270&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/CKJ/SFAA048
DO - https://doi.org/10.1093/CKJ/SFAA048
M3 - Article
C2 - 32897277
SN - 2048-8505
VL - 13
SP - 693
EP - 709
JO - Clinical Kidney Journal
JF - Clinical Kidney Journal
IS - 4
ER -